

INSPIREMD, INC.

FORM 8-K (Current report filing)

Filed 01/28/20 for the Period Ending 01/27/20

Telephone	(888) 776-6804
CIK	0001433607
Symbol	NSPR
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): January 27, 2020

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35731
(Commission
File Number)

26-2123838
(IRS Employer
Identification No.)

**4 Menorat Hamaor St.
Tel Aviv, Israel**
(Address of principal executive offices)

6744832
(Zip Code)

(888) 776-6804
(Registrant's telephone number, including area code)

N/A
(Former Name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of exchange on which registered</u>
Common Stock, par value \$0.0001 per share	NSPR	NYSE American
Warrants, exercisable for one share of Common Stock	NSPR.WS	NYSE American
Series B Warrants, exercisable for one share of Common Stock	NSPR.WSB	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On January 27, 2020, InspireMD, Inc. issued a press release announcing that its CGuard™ Carotid Embolic Prevention System (“EPS”) will be featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020 (the “Conference”). CGuard™ EPS will also be featured in three panel discussions and two scientific posters at the Conference. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 [Press Release dated January 27, 2020](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

InspireMD Inc.

Date: January 28, 2020

By: /s/ Craig Shore

Name: Craig Shore

Title: Chief Financial Officer

InspireMD's CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany

Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented

Tel Aviv, Israel— January 27, 2020 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid Embolic Prevention System (EPS) will be featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020 to be held from January 28th to the 31st at the Trade Fair Leipzig, Hall 2 in Leipzig, Germany. CGuard™ EPS will also be featured in three panel discussions and two scientific posters at the conference.

Live case:

Tuesday, 10:18 – 10:48 Live from Bergamo Technical Forum · Room 3

Case 17 – BG 03: male, 82 years (P-R)

Symptomatic high-risk coronary artery disease

Operators: F. Castriota, A. Micari

Additional presentations featuring CGuard™ EPS will include:

What: Immediate and one-month results from a prospective real-world multicentre clinical practice of CAS using the CGuard embolic prevention system:

The IRONGUARD 2 study P. Sirignano

When: January 28, 12:45 – 12:50 PM Central European Time

Where: Room 6 – Speaker's Corner

What: Accumulating long-term evidence for the MicroNet-covered stent safety, efficacy and durability in primary and secondary stroke prevention: 5-year data from the PARADIGM-Extend prospective academic trial P. Musialek

When: January 28, 12:50 – 12:55 PM Central European Time

Where: Room 6 – Speaker's Corner

What: OPTIMA I endovascular sequestration of high-risk carotid plaque using the CGuard™ MicroNET-covered embolic prevention stent system in consecutive patients with symptoms or signs of carotid stenosis-related brain injury: An intravascular ultrasound – controlled investigator-initiated multicentric multi-specialty study (CGuard OPTIMA) P. Musialek

When: January 28, 12:55 – 13:00 PM Central European Time

Where: Room 6 – Speaker’s Corner

What: Reconstruction of left subclavian artery using carotid technology B. Huasen

When: January 28, 14:30 – 14:35 PM Central European Time

Where: Main Arena 1

What: The use of CGuard stents; U.K. experience B. Huasen

When: January 28, 16:35 – 16:40 PM Central European Time

Where: Main Arena 1

The CGuard™ Carotid Embolic Prevention System will also be featured at the Company’s booth (16d2). InspireMD will be represented by its management, sales and clinical staff and welcomes all enquiries from clinicians and other interested parties.

About LINC

LINC is a leading global forum for new methods in the field of vascular medicine. LINC brings together medical professionals from different specialties around the world who perform endovascular interventions.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

888-776-6804

Email: craigs@inspiremd.com

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

Email: jeremy@lifesciadvisors.com
